Food Science and Biotechnology

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지

$PPAR_{\gamma}$ Ligand-binding Activity of Fragrin A Isolated from Mace (the Aril of Myristica fragrans Houtt.)

  • Lee, Jae-Young (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University) ;
  • Kim, Ba-Reum (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University) ;
  • Oh, Hyun-In (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University) ;
  • Shen, Lingai (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University) ;
  • Kim, Naeung-Bae (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University) ;
  • Hwang, Jae-Kwan (Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University)
  • Published : 2008.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Peroxisome proliferator-activated receptor-gamma ($PPAR_{\gamma}$), a member of the nuclear receptor of ligand-activated transcription factors, plays a key role in lipid and glucose metabolism or adipocytes differentiation. A lignan compound was isolated from mace (the aril of Myristica fragrans Houtt.) as a $PPAR_{\gamma}$ ligand, which was identified as fragrin A or 2-(4-allyl-2,6-dimethoxyphenoxy)-1-(4-hydroxy-3-methoxyphenyl)-propane. To ascertain whether fragrin A has $PPAR_{\gamma}$ ligand-binding activity, it was performed that GAL-4/$PPAR_{\gamma}$ transactivation assay. $PPAR_{\gamma}$ ligand-binding activity of fragrin A increased 4.7, 6.6, and 7.3-fold at 3, 5, and $10{\mu}M$, respectively, when compared with a vehicle control. Fragrin A also enhanced adipocytes differentiation and increased the expression of $PPAR_{\gamma}$ target genes such as adipocytes fatty acid-binding protein (aP2), lipoprotein lipase (LPL), and phosphoenol pyruvate carboxykinase (PEPCK). Furthermore, it significantly increased the expression level of glucose transporter 4 (GLUT4). These results indicate that fragrin A can be developed as a $PPAR_{\gamma}$ agonist for the improvement of insulin resistance associated with type 2 diabetes.

Keywords

References

  1. Kersten S, Desvergne B, Wahli W. R oles of PPARs in health and disease. Nature 405: 421-424 (2000) https://doi.org/10.1038/35013000
  2. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345 (1999) https://doi.org/10.1016/S0092-8674(00)81664-5
  3. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 139: 2748-2754 (1998) https://doi.org/10.1210/en.139.6.2748
  4. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821-827 (2001) https://doi.org/10.1038/414821a
  5. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771: 1065-1081 (2007) https://doi.org/10.1016/j.bbalip.2007.02.003
  6. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: A case study. Am. J. Med. 114: 299-306 (2003) https://doi.org/10.1016/S0002-9343(02)01529-2
  7. Tang WH, Maroo A. PPARgamma agonists: Safety issues in heart failure. Diabetes Obes. Metab. 9: 447-454 (2007) https://doi.org/10.1111/j.1463-1326.2006.00616.x
  8. Huang TH, Kota BP, Razmovski V, Roufoqalis BD. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin. Pharmacol. 96: 3-14 (2005) https://doi.org/10.1111/j.1742-7843.2005.pto960102.x
  9. Lee SY, Hwang JY, Kang MJ, Kim YM, Jung SH, Lee JH, Kim JI. Hypoglycemic effect of onion skin extract in animal models of diabetes mellitus. Food Sci. Biotechnol. 17: 130-134 (2008)
  10. Hattori M, Hada S, Shu YZ, Kakiuchi N, Namba T. New acyclic bis-phenylpropanoids from the aril of Myristica fragrans. Chem. Pharm. Bull. 35: 668-674 (1987) https://doi.org/10.1248/cpb.35.668
  11. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803-812 (1995) https://doi.org/10.1016/0092-8674(95)90193-0
  12. Han KL, Jung MH, Sohn JH, Hwang JK. Ginsenoside 20(S)-protopanaxatriol (PPT) activates peroxisome proliferators-activated receptor ${\gamma}$ in 3T3-L1 adipocyte. Biol. Pham. Bull. 29: 110-113 (2006) https://doi.org/10.1248/bpb.29.110
  13. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan CN, Spiegelman BM. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275: 1873-1877 (2000) https://doi.org/10.1074/jbc.275.3.1873
  14. Kim GS, Lee GY, Nedumaran B, Park YY, Kim KT, Park SC, Lee YC, Kim JB, Choi HS. The orphan nucler receptor DAX-1 acts as a novel transcriptional corepressor of $PPAR_{\gamma}$. Biochem. Bioph. Res. Co. 370: 264-268 (2008) https://doi.org/10.1016/j.bbrc.2008.03.098
  15. Spiegelman BM. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514 (1998) https://doi.org/10.2337/diabetes.47.4.507
  16. Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53: 409-435 (2002) https://doi.org/10.1146/annurev.med.53.082901.104018
  17. Baxa CA, Sha RS, Buelt MK, Smith AJ, Matarese V, Chinander LL, Boundy KL, Bernlohr DA. Human adipocyte lipid-binding protein: Purification of the protein and cloning of its complementary DNA. Biochemistry 28: 8683-8690 (1989) https://doi.org/10.1021/bi00448a003
  18. Kim SY, Park SM, Lee ST. Apolipoprotein C II is a novel substrate for matrix metalloproteinases. Biochem. Bioph. Res. Co. 339: 47-54 (2006) https://doi.org/10.1016/j.bbrc.2005.10.182
  19. Cadoudal T, Fouque F, Benelli C, Forest C. Glyceroneogenesis and PEPCK-C: Pharmacologucal targets in type 2 diabetes. Med. Sci. 24: 407-414 (2008)
  20. Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): Actions and defects in obesity and type II diabetes. Exp. Biol. Med. 230: 593-605 (2005) https://doi.org/10.1177/153537020523000901